Dynamic magnetic resonance imaging in the assessment of the response to Certolizumab Pegol in rheumatoid arthritis patients: results from a phase IIIb randomized study.

Mikkel Østergaard; Mette Bjørndal Axelsen; L.T.H. Jacobsson; C. Schaufelberger; Michael Sejer Hansen; J.W.J. Bijlsma; A. Dudek; M. Rell-Bakalarska; F. Staelens; R. Haake; B. Sundman-Engberg; Henning Bliddal

Dynamic magnetic resonance imaging in the assessment of the response to Certolizumab Pegol in rheumatoid arthritis patients: results from a phase IIIb randomized study.

Mikkel Østergaard, Mette Bjørndal Axelsen, L.T.H. Jacobsson, C. Schaufelberger, Michael Sejer Hansen, J.W.J. Bijlsma, A. Dudek, M. Rell-Bakalarska, F. Staelens, R. Haake, B. Sundman-Engberg, Henning Bliddal

Original language	English
Journal	Arthritis & Rheumatology
Volume	66
Issue number	Suppl. 11
Pages (from-to)	S518-19
Number of pages	2
ISSN	1537-2960
Publication status	Published - 2014

Cite this

Østergaard, M., Axelsen, M. B., Jacobsson, L. T. H., Schaufelberger, C., Hansen, M. S., Bijlsma, J. W. J., Dudek, A., Rell-Bakalarska, M., Staelens, F., Haake, R., Sundman-Engberg, B., & Bliddal, H. (2014). Dynamic magnetic resonance imaging in the assessment of the response to Certolizumab Pegol in rheumatoid arthritis patients: results from a phase IIIb randomized study. Arthritis & Rheumatology, 66(Suppl. 11), S518-19.

Dynamic magnetic resonance imaging in the assessment of the response to Certolizumab Pegol in rheumatoid arthritis patients: results from a phase IIIb randomized study. / Østergaard, Mikkel; Axelsen, Mette Bjørndal; Jacobsson, L.T.H. et al.
In: Arthritis & Rheumatology, Vol. 66, No. Suppl. 11, 2014, p. S518-19.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Østergaard, M, Axelsen, MB, Jacobsson, LTH, Schaufelberger, C, Hansen, MS, Bijlsma, JWJ, Dudek, A, Rell-Bakalarska, M, Staelens, F, Haake, R, Sundman-Engberg, B & Bliddal, H 2014, 'Dynamic magnetic resonance imaging in the assessment of the response to Certolizumab Pegol in rheumatoid arthritis patients: results from a phase IIIb randomized study.', Arthritis & Rheumatology, vol. 66, no. Suppl. 11, pp. S518-19.

@article{fa2a6fa665844951acf660547838de94,

title = "Dynamic magnetic resonance imaging in the assessment of the response to Certolizumab Pegol in rheumatoid arthritis patients: results from a phase IIIb randomized study.",

author = "Mikkel {\O}stergaard and Axelsen, {Mette Bj{\o}rndal} and L.T.H. Jacobsson and C. Schaufelberger and Hansen, {Michael Sejer} and J.W.J. Bijlsma and A. Dudek and M. Rell-Bakalarska and F. Staelens and R. Haake and B. Sundman-Engberg and Henning Bliddal",

year = "2014",

language = "English",

volume = "66",

pages = "S518--19",

journal = "Arthritis & Rheumatology",

issn = "1537-2960",

publisher = "eMedguides.com",

number = "Suppl. 11",

}

TY - ABST

T1 - Dynamic magnetic resonance imaging in the assessment of the response to Certolizumab Pegol in rheumatoid arthritis patients: results from a phase IIIb randomized study.

AU - Østergaard, Mikkel

AU - Axelsen, Mette Bjørndal

AU - Jacobsson, L.T.H.

AU - Schaufelberger, C.

AU - Hansen, Michael Sejer

AU - Bijlsma, J.W.J.

AU - Dudek, A.

AU - Rell-Bakalarska, M.

AU - Staelens, F.

AU - Haake, R.

AU - Sundman-Engberg, B.

AU - Bliddal, Henning

PY - 2014

Y1 - 2014

M3 - Conference abstract in journal

SN - 1537-2960

VL - 66

SP - S518-19

JO - Arthritis & Rheumatology

JF - Arthritis & Rheumatology

IS - Suppl. 11

ER -